Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Approval to dramatically change CAR-T therapies landscape
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated